All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Corey Cutler, Dana-Farber Cancer Institute, Boston, US. We asked, when should we consider allogeneic stem cell transplantation for patients with MDS?
In this video, Cutler talks about the results from the Blood and Marrow Transplant Clinical Trials Network study 1102. Read a summary of the data presented here.
When should we consider allo-SCT for patients with MDS?
Editorial theme | Genetic pathogenesis of MDS: Translating molecular advances into better diagnosis and prognosis of CCUS and MDS
The last 30 years of advances in molecular biology and high-throughput techniques have significantly impacted the...
How should we manage HMA failure?
During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Valeria Santini, University of Florence, Florence, IT. We asked, How should we...
Subscribe to get the best content related to MDS delivered to your inbox